✦ LIBER ✦

Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial

✍ Scribed by Orazio Caffo; Teodoro Sava; Evi Comploj; Annamaria Fariello; Fable Zustovich; Romana Segati; Cosimo Sacco; Francesco Valduga; Gianluigi Cetto; Enzo Galligioni

Book ID: 109054148
Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 149 KB
Volume: 102
Category: Article
ISSN: 1464-4096
DOI: 10.1111/j.1464-410x.2008.07779.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Docetaxel/gemcitabine or cisplatin/gemci

Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial

✍ D. Binder; H. Schweisfurth; C. Grah; C. Schäper; B. Temmesfeld-Wollbrück; G. Sie 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 340 KB

Early hormonal data from a multicentre p

Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer

✍ Ruth E. Langley; Ian F. Godsland; Howard Kynaston; Noel W. Clarke; Stuart D. Ros 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 126 KB

Non-pegylated liposomal doxorubicin comb

Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial

✍ S. Del Barco; R. Colomer; L. Calvo; I. Tusquets; E. Adrover; P. Sánchez; J. Rifà 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 220 KB

A multicenter randomized phase II study

A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients

✍ Jean-Yves Pierga; Suzette Delaloge; Marc Espié; Etienne Brain; Brigitte Sigal-Za 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 236 KB

A phase I/randomized phase II, non-compa

A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC)

✍ Roger B. Cohen; Corey J. Langer; George Rajan Simon; Peter David Eisenberg; John 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 387 KB